Minimal Access Versus Conventional Latissimus Dorsi Flap Harvest for Breast Reconstruction
For patients refusing implants for breast reconstruction after cancer surgery, autologous tissue flap reconstruction using the latissimus dorsi muscle is an alternative. Conventional surgery leaves a long incision on the back, affecting aesthetics and quality of life. Minimal access techniques result in a smaller, more concealable scar. While previous studies suggest its safety and effectiveness, most are retrospective. To further validate patient satisfaction and short-term outcomes, a prospective, randomized…
Conditions studied
Breast Neoplasms
About this study
For patients refusing implants for breast reconstruction after cancer surgery, autologous tissue flap reconstruction using the latissimus dorsi muscle is an alternative. Conventional surgery leaves a long incision on the back, affecting aesthetics and quality of life. Minimal access techniques result in a smaller, more concealable scar. While previous studies suggest its safety and effectiveness, most are retrospective. To further validate patient satisfaction and short-term outcomes, a prospective, randomized controlled trial comparing minimal access with conventional surgery is planned. The primary endpoint is Breast Q-satisfaction with back score at 6 months. Secondary outcomes include other Breast Q subscales, surgical metrics, and complications. The study aims to enroll 94 patients in total, providing evidence for surgical decision-making in breast cancer reconstruction.
Interventions
- Device: minimal access breast reconstruction with a latissimus dorsi muscle flap — minimal access breast reconstruction with a latissimus dorsi muscle flap
- Device: conventional breast reconstruction with a latissimus dorsi muscle flap — conventional breast reconstruction with a latissimus dorsi muscle flap
Primary outcomes
- Breast Q-satisfaction with back (6 months)
Eligibility information
Study locations
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120 China
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.